Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29254327 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL20533381 | 0.81 | ALDH1A1 (0.58) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL7305803 | 0.81 | ALDH1A1 (0.58) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL12406395 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL16451613 | 0.79 | ALDH1A1 (0.56) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL6474189 | 0.79 | ALDH1A1 (0.56) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL24361098 | 0.78 | ALDH1A1 (0.54) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL15371097 | 0.78 | ALDH1A1 (0.54) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL3213948 | 0.76 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL12705028 | 0.76 | ALDH1A1 (0.57) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854140-B1 | Vitronectin receptor antagonists, their production and their use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-6867208-B2 | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030119785-A1 | Vitronectin receptor antagonists, their preparation and use | HOECHST AKTIENGESELLSCHAFT AND GENENTECH INC. | 2003-06-26 | — | — | US | disclosed |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | GENENTECH, INC. AND HOECHST AKTIENGESELLSCHAFT | 2003-02-06 | — | — | US | disclosed |
| US-6482821-B2 | ANTIINFLAMMATORY AGENTS; ANTITUMOR AGENTS; CARDIOVACULAR DISORDERS | HOECHST AKTIENGELLSCHAFT (DE) | 2002-11-19 | — | — | US | disclosed |
| US-6387895-B1 | BONE DISORDERS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| EP-1165567-A2 | SULFAMATE CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010011087-A1 | Vitronectin receptor antagonists, their preparation and their use | WEHNER VOLKMAR (DE) | 2001-08-02 | — | — | US | disclosed |
| US-6218387-B1 | AS INHIBITORS OF BONE RESORPTION BY OSTEOCLASTS, FOR INHIBITING TUMOR GROWTH OR TUMOR METASTASIS, INHIBITING INFLAMMATION, OR FOR TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES, NEUROPATHIES OR RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| US-6207663-B1 | AS INHIBITORS OF BONE RESORPTION, TUMOR GROWTH, TUMOR METASTASIS, OR INFLAMMATION, OR FOR THE TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS, NEPHROPATHIES OR RETINOPATHIES | HOECHST ATKIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| WO-2000058314-A2 | SULFAMATE CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 2000-10-05 | — | — | WO | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
| US-5990145-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-23 | — | — | US | disclosed |
| EP-0854145-A2 | Vitronectin receptor antagonists, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-22 | — | — | EP | disclosed |
| EP-0854140-A2 | Vitronectin receptor antagonists, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119785-A1 | Vitronectin receptor antagonists, their preparation and use | ADGRF1, CFD, ADGRE5 | ALDH1A1 3332/4885CA12 2771/4885CA1 3367/4885 |
| US-20010011087-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, BSG, ADGRE5 | ALDH1A1 3191/4885CA12 3274/4885CA1 3434/4885 |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, ADGRE5, BSG | ALDH1A1 3286/4885CA12 3181/4885CA1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.